

KIDNEYWEEK²⁰¹⁵

San Diego, CA • Nov 3-8

Saturday, November 7, 10:30 a.m. – 12:30 p.m.

Oral Abstract Session

High-Impact Clinical Trials

Hall D

Moderators:

Linda F. Fried, MD, MPH, FASN, and Sushrut S. Waikar, MD

-
- 10:30 a.m.** **Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease** — Christoph Wanner, John M. Lachin, David H. Fitchett, Silvio E. Inzucchi, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans-Jürgen Woerle, Uli Christian Brödl, Bernard Zinman. Würzburg, Germany.
- 10:45 a.m.** **High Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery** — Frederic Tremaine Billings, Chad E. Wagner, Patty Hendricks, Yaping Shi, Michael R. Petracek, Nancy J. Brown. Nashville, TN.
- 11:00 a.m.** **Effect of Methylprednisolone on Acute Kidney Injury in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass** — Amit X. Garg, Richard P. Whitlock. London, ON, Canada.
- 11:15 a.m.** **The NEFIGAN Trial: NEFECON, a Novel Targeted Release Formulation of Budesonide, Reduces Proteinuria and Stabilizes eGFR in IgA Nephropathy Patients at Risk of ESRD** — Bengt C. Fellstrom, Rosanna Coppo, John Feehally, Jürgen Floege, Johan W. De Fijter, Alan G. Jardine, Francesco Locatelli, Bart D. Maes, Alex Mercer, Fernanda Ortiz, Manuel Praga, Søren Schwartz Sørensen, Vladimir Tesar. Uppsala, Sweden.
- 11:30 a.m.** **Randomized Trial on Efficacy of Mycophenolate Mofetil versus Tacrolimus in Maintaining Remission in Children with Steroid Resistant Nephrotic Syndrome** — Aditi Sinha, Arvind Baggs. New Delhi, India.
- 11:45 a.m.** **Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients with Twice-Yearly Denosumab: A Randomized Controlled Trial** — Rudolf P. Wuthrich, Diana P. Frey, Jens Gunther Brockmann, Thomas Fehr, Thomas F. Mueller, Lanja Saleh, Arnold Von Eckardstein, Nicole Graf, Marco Bonan. Zürich, Switzerland.
- 12:00 p.m.** **Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients with Uremic Pruritus** — Vandana S. Mathur, Jayant Kumar, Paul W. Crawford, Howard Hait, Thomas Sciascia. Woodside, CA.
- 12:15 p.m.** **The Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study: A Randomised Placebo-Controlled Trial** — Ashley B. Irish. Perth, Australia.

KIDNEYWEEK²⁰¹⁵

San Diego, CA • Nov 3-8

Saturday, November 7 9:30 a.m. – 4:30 p.m.

Posters

Late-Breaking Clinical Trial Posters

Exhibit Halls A/B

- SA-PO1091** **The Remote Ischemic Preconditioning in Cardiac Surgery Trial (Remote IMPACT)** — *Michael Walsh*, Hamilton, ON, Canada.
- SA-PO1092** **Nephrotoxicity of Invasive and Noninvasive Coronary Angiography: Randomized Controlled Study of Intracoronary and Intravenous Contrast Agent Administration** — *Eva Schönenberger, Patricia D. Bady, Peter Martus, Elke Zimmermann, Michael Laule, Marc Dewey*. Berlin, Germany.
- SA-PO1093** **Efficacy and Safety of Bosutinib in Autosomal Dominant Polycystic Kidney Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study** — *Kazimierz Ciechanowski, Vladimir Tesar, York P. Pei, Irina Barash, Megan Shannon, Ruifeng Li, Jason Williams, Matteo Levisetti, Steven Arkin, Andreas L. Serra*. Szczecin, Poland.
- SA-PO1094** **Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD: A Randomized Controlled Trial** — *Osama W. Amro, Jessica K. Paulus, Farzad Noubary, Ronald D. Perrone*. Boston, MA.
- SA-PO1095** **A Phase 2, Double-Blind, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis** — *James A. Tumlin, Flavio Vincenti, Fernando C. Fervenza, Kirk N. Campbell, Montserrat M. Diaz Encarnación, Manuel Praga, Denyse Thornley-Brown, Francisco Verissimo Veronese, Beverly Accomando, Sara Engstrand, Steven R. Ledbetter, Julie Lin, John F. Neylan*. Chattanooga, TN.
- SA-PO1096** **Effects of Sustained-Release Beraprost Sodium in Patients with Primary Glomerular Disease or Nephrosclerosis: The CASSIOPEIR Study** — *Toshiro Fujita, Xueqing Yu, Suhngwon Kim, Hidetomo Nakamoto, Hideki Origasa, Hajimu Kurumatani, Takashi Kiriyama*. Tokyo, Japan.
- SA-PO1097** **Corticosteroid Monotherapy versus Combined Immunosuppression in IgA Nephropathy: Insights from the STOP-IgAN Trial** — *Jürgen Floege, Thomas Rauen, Frank Eitner, Christina Fitzner, Ralf-Dieter Hilgers*. Aachen, Germany.
- SA-PO1098** **A Randomized Trial of Rituximab in Advanced IgA Nephropathy** — *Richard A. Lafayette, Pietro A. Canetta, Brad H. Rovin, Gerald B. Appel, Marie C. Hogan, Stephen B. Erickson, Fernando C. Fervenza*. Stanford, CA.
- SA-PO1099** **Establishing Endpoints for Lupus Nephritis Clinical Trials: Progress by the Kidney Health Initiative/Lupus Nephritis Trials Network Collaboration** — *Brad H. Rovin, Meggan Mackay, Joanna Stein, Maria Dall'Era, Kenneth Kalunian, Martin L. Lesser, Melissa West*. Columbus, OH.
- SA-PO1100** **Grazoprevir (GZR)/Elbasvir (EBR) Treatment of Hepatitis C Virus (HCV) Infection in Patients with Chronic Kidney Disease Stage 4/5: Final Results of the C-SURFER Phase 3 Study** — *David Roth, Annette Bruchfeld, Paul Martin, David R. Nelson, Marcelo Silva, Howard Monsour, Laurent Alric, Shuyan Wan, Beth Jackson, Bach-Yen Nguyen, Janice Wahl, Eliav Barr, Wayne L. Greaves*. Miami, FL.
- SA-PO1101** **Long-Term (52-Week) Efficacy and Safety of ZS-9 in the Treatment of Hyperkalemia: Interim Results from a Phase 3 Open-Label, Multi-Center, Multi-Dose Maintenance Study** — *James A. Tumlin, Mikhail Kosiborod, Pablo E. Pergola, Wajeh Y. Qunibi, David K. Packham, Simon D. Roger, Edgar V. Lerma, Steven Fishbane, Henrik S. Rasmussen, Bruce S. Spinowitz*. Chattanooga, TN.
- SA-PO1102** **Interleukin-1 Inhibition and Vascular Function in Patients with Chronic Kidney Disease (CKD): A Randomized Controlled Trial** — *Kristen L. Nowak, Michel Chonchol, Talat Alp Ikizler, Heather Farmer, Natjale Salas, Rafia I. Chaudhry, Wei Wang, Gerard John Smits, Adriana Hung*. Aurora, CO.
- SA-PO1103** **Abstract Withdrawn.**
- SA-PO1104** **Impact of Vitamin D Supplementation on Endothelial and Vascular Function in Patients with Chronic Kidney Disease: A Randomized, Double-Blind, Placebo-Controlled Trial** — *Vivek Kumar, Ashok Kumar Yadav, Vinod Sharma, Manphool Singhal, Anupam Lal, Debasish Banerjee, Vivekanand Jha*. Chandigarh, India.
- SA-PO1105** **Effect of Cholecalciferol vs. Calcitriol on Vascular Endothelial Function in CKD: A Randomized Active-Controlled Trial** — *Jessica B. Kendrick, Gerard John Smits, Emily Decker, Heather Farmer, Michel Chonchol*. Denver, CO.

- SA-PO1106** **Vitamin D Receptor Activation and Dietary Sodium Restriction to Reduce Residual Albuminuria in Chronic Kidney Disease** — *Martin H. De Borst, Charlotte A. Keyzer, Fenna van Breda, Marc G. Vervloet, Gozewijn Dirk Laverman, Marc H. Hemmelder, Wilbert M. Janssen, Hidde Jan Lambers Heerspink, Stephan J.L. Bakker, Gerjan Navis.* Groningen, Netherlands.
- SA-PO1107** **Vascular Function and Uric Acid Lowering via Allopurinol in Stage III CKD: Results of a Double-Blinded Randomized Placebo-Controlled Study** — *Diana I. Jalal, Emily Decker, Loni J. Perrenoud, Nina Bispham, Tapan Mehta, Gerard John Smits, Richard J. Johnson.* Aurora, CO.
- SA-PO1108** **Podocyturia Is an Earlier and Superior Predictor of Cardiovascular Outcomes Than Is Albuminuria** — *Assaad Antoine Eid, Robert Habib, Kamal F. Badr.* Beirut, Lebanon.
- SA-PO1109** **Empagliflozin Reduces Microalbuminuria and Macroalbuminuria in Patients with Type 2 Diabetes** — *David Cherney, Søren Søgaard Lund, Bruce A. Perkins, Per-Henrik Groop, Mark E. Cooper, Stefan Kaspers, Susanne Crowe, Hans-Jürgen Woerle, Maximilian von Eynatten.* Toronto, ON, Canada.
- SA-PO1110** **Vadadustat, a Novel Oral Treatment for Anemia of Chronic Kidney Disease, Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimulating Agents** — *Volker H. Haase, Charlotte S. Hartman, Bradley J. Maroni, Ramin Farzaneh-Far, Peter A. McCullough.* Nashville, TN.
- SA-PO1111** **Autologous Erythropoietin Production by the TARGT Gene Therapy Platform Maintains Stable Hb for 6-12 Months in ESRD Patients without the Need for ESA Administration** — *Shany Blum, Nir Shapir, Reem Miari, Shai Efrati, Pablo E. Pergola, Garry A. Neil.* Misgav, Israel.
- SA-PO1112** **Monitoring in Dialysis (MiD) Study: Exploring the Timeline and Etiology of Increased Arrhythmias in Hemodialysis (HD) Patients** — *Prabir Roy-Chaudhury, Don E. Williamson, James A. Tumlin, Vijay K. Kher, Vikranth Reddy, David M. Charytan, Suresh Chandra Tiwari, Saurabh Pokhariyal, Amber S. Podoll.* Tucson, AZ.
- SA-PO1113** **The Occurrence of Cardiac Arrhythmias in Hemodialysis Patients is Linked to the Hemodialysis Procedure and to Electrolyte Abnormalities as Recorded by Implantable Loop Recorders** — *Christian Combe, Antoine Benard, H  l  ne Savel, F. Sacher.* Bordeaux, France.
- SA-PO1114** **Abstract Withdrawn.**
- SA-PO1115** **Comparison of the Efficacy and Safety of Intravenous (IV) Etelcalcetide (AMG 416) and Oral Cinacalcet (CIN) in Patients on Hemodialysis (HD) with Secondary Hyperparathyroidism (SHPT)** — *Kevin J. Martin, Geoffrey A. Block, Sunfa Cheng, Bastian Dehmel, Reshma Kewalramani, David M. Spiegel, Hao Wang, Glenn Matthew Chertow.* St Louis, MO.
- SA-PO1116** **A Trial Assessing Use of a Wearable Artificial Kidney (WAK) in Patients Undergoing Maintenance Hemodialysis** — *Victor Gura, Matthew B. Rivara, Raj P. Munshi, Scott D. Bieber, Masoud Beizai, Carlos J. Ezon, Larry Kessler, Jonathan Himmelfarb.* Beverly Hills, CA.
- SA-PO1117** **CR845, a Novel Kappa Opioid Receptor Agonist Reduces Moderate-to-Severe Pruritus and Improves Quality of Life in Chronic Kidney Disease Patients Undergoing Hemodialysis** — *Robert Spencer, Vandana S. Mathur, James A. Tumlin, Joseph W. Stauffer, Frederique Menzaghi.* Shelton, CT.
- SA-PO1118** **The ASSertID Study: Feasibility Randomised Controlled Trial of Drug Treatment for Depression in Patients on Haemodialysis** — *Ayman Guirguis, Michael K. Almond, Joseph Chilcot, Andrew Davenport, Clara Day, Naomi Fineberg, Karin Friedli, Benjamin Spencer, David Wellsted, Ken Farrington.* Hatfield, Hertfordshire, United Kingdom.
- SA-PO1119** **Randomised Controlled Trial to Determine the Appropriate Time to Initiate Peritoneal Dialysis after Insertion of Catheter to Minimise Complications** — *Helen G. Healy, George T. John, Edward Yeoh, Nicola Williams, Thin M. Han, Lakshmanan Jeyaseelan, Kavitha Ramanathan, Dwarakanathan Ranganathan.* Brisbane, Queensland, Australia.
- SA-PO1120** **The Effects of Normal Saline and an Acetate-Buffered Crystalloid Solution on Hyperkalemia in Deceased Donor Renal Transplantation: A Randomized Blinded Trial** — *Laura Elisabeth Harris, Peter F. Mount, Francesco L. Ierino, David A. Story, Glenn M. Eastwood, Larry McNicol, Rinaldo Bellomo, Laurence Weinberg.* Heidelberg, Australia.
- SA-PO1121** **Abstract Withdrawn.**
- SA-PO1122** **Eculizumab in Prevention of Acute Antibody-Mediated Rejection in Sensitized Deceased-Donor Kidney Transplant Recipients: Updated 12-Month Outcomes** — *D. Glotz, G. Russ, Lionel Rostaing, Christophe M. Legendre, Steven J. Chadban, J. Grinyo, Nizam Mamode, Gunnar Tufveson, Lionel Couzi, P. Riggotti, Y. Lebranchu, S. Sandrini, W. Marks.* Paris, France.
- SA-PO1123** **Impact of De Novo Donor Specific Antibodies on Graft Outcomes in Kidney Transplant Recipients Following Early Switch From Calcineurin Inhibitor to Everolimus: Analysis of the ELEVATE Trial** — *Johan W. De Fijter, Hallvard Holdaas, Patricia M. Lopez, Peter Bernhardt, Zailong Wang, Frans Claas, Wolfgang Arns, Josep M. Cruzado, Markus van der Giet.* Leiden, Netherlands.
- SA-PO1124** **Donor-Derived Cell-Free DNA in Plasma Increases with Rejection and Decreases after Treatment in Kidney Transplant Recipients** — *Marica Grskovic, Brian Christie, David Hiller, Robert Woodward, Jim Yee, Flavio Vincenti.* Brisbane, CA.